Regeneron Pharmaceuticals, Inc. has announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited to acquire exclusive clinical development and commercial rights for a dual GLP-1/GIP receptor agonist, HS-20094, outside of the Chinese Mainland, Hong Kong, and Macau. Currently in Phase 3 testing, this therapeutic candidate has been studied in over 1,000 patients as a weekly subcutaneous injection, showing promising efficacy and safety data. The agreement includes an upfront payment of $80 million to Hansoh, with potential additional payments up to $1.93 billion based on achievement of development, regulatory, and sales milestones. Regeneron aims to integrate this candidate into its portfolio to address muscle loss and other obesity-related comorbidities.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。